CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases. Our mission is to alleviate human suffering and improve patients' quality of life through innovation and collaboration. We are committed to performing our duties with respect, integrity, and a unified vision of serving humanity. 

CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.

Leronlimab is a humanized monoclonal antibody that is a once-a-week subcutaneous injection that can also be administered intravenously. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.

About Our Company

Arrow Down

Leronlimab for NASH

A Fully Humanized Monoclonal Antibody

Leronlimab (PRO 140) is a fully humanized monoclonal antibody directed against CCR5. The CCR5 receptor exists in the liver on the surface of hepatocytes and stellate cells. Stellate cells are the cells that produce scar tissue in the liver, which can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. It is critical to have therapeutic options to resolve NASH before it progresses to later life-threatening stages. There are multiple comorbidities associated with NASH including a higher cardiovascular mortality rate.

Leronlimab for Cancer

Developing CCR5 Technology in Cancer Indications

Based on the work of leading oncologists and researchers who played an instrumental role in identifying the role of CCR5 in cancer indications, we continue to explore the role of leronlimab in oncology and have obtained promising results from various pre-clinical studies.